In the United States, more than 70,000 people are diagnosed with non-Hodgkin’s lymphoma each year, which is caused by excessive proliferation of immune cells in the body’s lymph nodes. The most common is diffuse large B-cell lymphoma (DLBCL), which accounts for about 1/3 of lymphomas, and about half of these tumors are resistant to chemotherapy and immunotherapy. Kamwe iyo lymphoma painotangira kubva kune lymphatic tishu, kuwanda kwemasero kunokonzeresa kuti chimiro chetissue chibvaruke, uye maseru anozoburitswa kumagetsi emagetsi senge kuyerera kwemvura.
Vatsvakurudzi vakaongorora kuti aya masimba emvura anoenderana sei nechubhu kuramba, uye vakagadzira "lymphoma microreactor" chishandiso chinoburitsa munhu lymphoma mukuyerera kwemvura, yakafanana nemapatani mumidziyo yeLymphatic uye mamwe ma lymph node.
Chikwata cheparutivi-kuyerera microreactor chinosanganisira chetsika tsika kamuri yakabatana neyetsika yepakati (yemvura) kamuri kuburikidza neyakaganhurirwa kuramba chiteshi, iyo inononoka kuyerera kwemvura kutevedzera lymphatic midziyo uye lymph node zvikamu. Pakuyedza dzakasiyana subpopulations dzeDLCBL lymphoma, timu yekutsvagurudza yakawana kuti mamwe ma subtypes akarongedzwa zvinoenderana neshanduko muB B maseru receptor mamorekuru akawanikwa pasero pevhu vakapindura zvakasiyana nemauto emvura. Chikwata chakaona kuti simba remvura rinogadzirisa mataurirwo emazinga einosanganiswa-adhesin uye B maseru receptors. Kune kuyambuka-kupindirana pakati peinopindirana uye B maseru ekugamuchira maseru, ayo anogona kubatsira kutsanangura kushomeka kwemamwe mamota.
What is remarkable is that the same tumor subtype responds differently to mechanical forces. If we can understand the role of biophysical stimulation, we can know why some lymphomas are sensitive to treatment, while others are refractory, then we will be able to treat more patients. It is important to understand the factors that regulate B-cell receptor signaling because this pathway is a key target for new therapeutic drugs, and several of them are in clinical trials. Kuti uwane rumwe ruzivo, ndapota fona CancerFax.
